Hormonal
Lixisenatide, high-dose canagliflozin (300 mg/day), empagliflozin, and dapagliflozin are associated with a reduced risk of acute kidney injury compared to control treatments.
If you are taking lixisenatide, high-dose canagliflozin, empagliflozin, or dapagliflozin, you may have a lower risk of acute kidney injury compared to those not on these medications. Continue to follow your doctor's recommendations for kidney function monitoring, as these benefits do not eliminate the need for standard care.
In contrast, lixisenatide, high-dose canagliflozin (300 mg/day), empagliflozin, and dapagliflozin were associated with a reduced AKI risk.
Why this rating
Based on a network meta-analysis of 67 RCTs. The protective effects for these agents are consistent across subgroup analyses.
Source
Differential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis
Chih-Sung Liang et al. · International Journal of Molecular Sciences · 2026
DOI 10.3390/ijms27094137
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →